Recommendations of Polish Myeloma Group concerning diagnosis and therapy of multiple myeloma;Zalecenia Polskiej Grupy Szpiczakowej dotycza̧ce rozpoznawania i leczenia szpiczaka plazmocytowego

Acta Haematologica Polonica

Volumn 40, Issue 3, 2009, Pages 753-782

  Dmoszyńska, Anna ^a   Kraj, Maria ^b   Walter Croneck, Adam ^a   Walewski, Jan ^c   Mańko, Joanna ^a   Dytfeld, Dominik ^d   Komarnicki, Mieczysław ^e   Hellmann, Andrzej ^f   Skotnicki, Aleksander ^g  

^a Klinika Hematoonkologii I Transplantacji Szpiku UM W Lublinie   (Poland)

^b Oddział Chorób Układu Chłonnego IHiT W Warszawie ^*  (Poland)

^c INSTITUTE OF ONCOLOGY   (Poland)

^d Klinika Hematologii I Chorób Rozrostowych Uk adu Krwiotwórczego UM W Poznaniu   (Poland)

^e Klinika Hematologii I Nowotworów Krwi I Transplantacji Szpiku UM we Wroc awiu   (United States)

^f Klinika Hematologii I Transplantologii GUM W Gda sku   (Poland)

^g JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Diagnosis; Multiple myeloma; New drugs; Therapeutic considerations

Indexed keywords

ALPHA INTERFERON; BENDAMUSTINE; BORTEZOMIB; CARMUSTINE; CLODRONIC ACID; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; LOMUSTINE; MELPHALAN; METHYLPREDNISOLONE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PAMIDRONIC ACID; PREDNISONE; RECOMBINANT ERYTHROPOIETIN; THALIDOMIDE; VINCRISTINE;

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER RADIOTHERAPY; DRUG MECHANISM; GENETIC ANALYSIS; HUMAN; MULTIPLE MYELOMA; POLAND; PRACTICE GUIDELINE; PROGNOSIS; REVIEW; STEM CELL MOBILIZATION;

EID: 70450216512     PISSN: 00015814     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Attal M, Harousseau JL, Leyvraz S i wsp. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood. 2006; 108: 3289-3294
2. Baur A., Stabler A., Nagel D. i wsp Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon? Cancer. 2002 15; 95(6):1334-1345
3. Baur-Melnyk A., Buhmann S., Durr H. i wsp Role of MRI for the diagnosis and prognosis of multiple myeloma. Eur J Radiol. 2005; 55(1):56-63. (Pubitemid 40798488)
4. Bilińska M, Usnarska-Zubkiewicz L, Dmoszyńska A. Polineuropatia wywołana talidomidem i bortezomibem u chorych na szpiczaka mnogiego, możliwości leczenia bólu neuropatycznego. Zalecenia Polskiej Grupy Szpiczakowej. (Thalidomide- and bortezomib-induced neuropathy in multiple myeloma, possibility of treatment of neuropathic pain. Recommendations of the Polish Meyloma Study Group.) Współczesna Onkologia 2008; 12: 441-446
5. Bladé J, Samson D, Reece D, i wsp Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998; 102(5): 1115-1123
6. Blade J. Rosinol I.: Advances in therapy of multiple myeloma. Curr. Opin. Oncol. 2008; 20: 697-704
7. Blade J. Rosinol L.: Changing paradigms in the teratment of multiple myeloma. Haematologica 2009; 94:163-166.
8. Brenner H., Gondos A., Pulte D.: Expected long - term survival of patients diagnosed with multiple myeloma. Haematologica 2009; 94:270-275
9. Brenner H., Gondos A., Pulte D.: Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008; 111: 2521-2526
10. Didkowska J, Wojciechowska U, Tarkowski W, Zatoński W: Nowotwory złośliwe w Polsce w 2005 roku. Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie, Warszawa 2007.
11. Dimopoulos M., Moulopoulos A., Smith T. i wsp. Risk of disease progression in asymptomatic multiple myeloma. Am J Med. 1993; 94(1):57-61.
12. Dimopoulos M., Spencer A., Attal M., i wsp. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N. Eng. J. Med 2007; 357: 2123-2132
13. Dispenzieri A, Kyle RA, Katzmann JA i wsp. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood. 2008; 111(2):785-789
14. th ed. Wolter Kluwer/ Lippincott Williams & Wilkins 2009, 2372-2438.
15. Walter-Croneck A, Dmoszyńska A, Piszcz J. i wsp. Ocena skuteczności i bezpieczeństwa stosowania schematu CTD (cyklofosfamid, talidomid, deksametazon) u chorych na szpiczaka mnogiego - raport Polskiej Grupy Szpiczakowej). Acta Haematologica Polonica. 2009; 38: 149-150.
16. Durie BG, Harousseau JL, Miguel JS, i wsp. International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia. 2006; 20(9): 1467-73. Epub 2006 Jul 20. Erratum in: Leukemia. 2006; 20(12):2220. Leukemia. 2007; 21(5): 1134.
17. Durie BG, Kyle R., Belch A. i wsp. (Scientific Advisors of the International Myeloma Foundation): Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J. 2003; 4(6): 379-98. Review. Erratum in: Hematol J. 2004; 5(3):285.
18. Durie BG, Salmon SE.: A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 1975; 36(3):842-854
19. Dytfeld D, Sosnowski P, Czyz A i wsp. The role of the magnetic resonance in diagnosis of multiple myeloma, Pol Merkur Lekarski. 2007;23(134):85-88
20. Facon T, Mary JY, Hulin C, i wsp. Intergroupe Francophone du Myélome. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial Lancet 2007; 370(9594):1209-1218 (Pubitemid 47516593)
21. Fonseca R, Barlogie B, Bataille R i wsp. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. 2004; 64(4):1546-1558
22. Fonseca R, Blood E, Rue M i wsp. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003; 101(11): 4569-4575
23. Greipp PR, San Miguel J, Durie BG i wsp. International staging system for multiple myeloma. J Clin Oncol. 2005; 23(15): 3412-3420
24. Harousseau JI.: Role of stem cell transplantation in multiple myeloma. Hematol. Oncol. Clin North Am. 2007; 21: 1157-1174
25. Hus I, Dmoszynska A, Manko J, i wsp. An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma. Br J Cancer. 2004; 91(11): 1873-1879 (Pubitemid 40065514)
26. Kastritis E, Mitsiades CS, Dimopoulos MA i wsp. Management of relapsed and relapsed refractory myeloma. Hematol Oncol Clin North Am. 2007; 21: 1175-1215
27. Kristinsson SY, Landgren O, Dickman PW, i wsp. Patterns of survival in multiple myeloma: a population - based study of patients diagnosed in Sweden from 1973-2003. J. Clin. Oncol. 2007; 25: 1993-9
28. Kumar SK, Rajkumar SV, Dispenzieri A, i wsp. Improved survival in multiple mueloma and the impact of novel therapies. Blood 2008; 111: 2516-2520
29. Kyle RA, Rajkumar SV: Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009; 23: 3-9.
30. th ed. Wolter Kluwer/ Lippincott Williams & Wilkins 2009, 2352-2371.
31. Mangles SE, Abdalla SH. CTD treatment of myeloma - a single institution's experience. Haematologica suppl 2 2007; 92: PO-654 (abstr.).
32. McKenna RW, Kyle RA, Kuehl WM, i wsp. (Eds.): WHO classification of tumours of haematopoietic and lymphoid tissues. IARC: Lyon 2008, str. 200-213.
33. Niesvizky R, Jayabalan DS, Christos PJ i wsp. BiRD (Biaxin/Revlimid /dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood. 2008; 111: 1101-1109
34. Oakervee HE, Popat R, Curry N, i wsp. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol. 2005; 129(6): 755-762 (Pubitemid 40904525)
35. Offidani M, Corvatta L, Marconi M i wsp. Low-dose thalidomide with pegylated liposomal doxorubicin and high dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study. Haematologica. 2006; 91: 133-136
36. Palumbo A, Ambrosini MT, Benevolo G i wsp. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood. 2007; 109: 2767-2772
37. Palumbo A, Bringhen S, Caravita T, i wsp. Italian Multiple Myeloma Network, GIMEMA. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet. 2006; 367(9513): 825-31. Comment in: Lancet. 2006; 367(9527):1977; author reply 1977-8. Lancet. 2006; 367(9513): 791-792
38. Palumbo A, Bringhen S, Liberati AM, i wsp. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood. 2008; 112(8): 3107-3114
39. Palumbo A, Falco P, Corradini P i wsp. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA-Italian Multiple Myeloma Network. J Clin Oncol. 2007; 25: 4459-4465 (Pubitemid 350063804)
40. Palumbo A, Facon T, Sonnenveld P, i wsp. Thalidomide for the treatment of multiple myeloma: 10 years later. Blood 2008; 11: 3968-3972
41. Rajkumar SV, Kyle RA, Therneau TM i wsp. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 2005; 106(3): 812-817
42. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR. ECOG Phase III trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed myeloma: a clinical trial co-ordinated by the ECOG. J. Clin. Oncol. 2006; 24: 431-436
43. Richardson PG, Sonneveld P, Schuster M, i wsp. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007; 110(10): 3557-3560
44. Richardson PG, Sonneveld P, Schuster MW, i wsp. Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005; 352(24): 2487-2498
45. San Miguel JF, Schlag R, Khuageva NK, i wsp.: VISTA Trial Investigators. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008; 359: 906-917
46. San-Miguel JF, Richardson PG, Sonneveld P i wsp. Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia. 2008; 22: 842-849.
47. Smith A, Wisloff F, Samson D; UK Myeloma Forum; Nordic Myeloma Study Group; British Committee for Standards in Haematology: Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol. 2006; 132(4):410-451
48. Snozek CL, Katzmann JA, Kyle RA i wsp. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leukemia. 2008; 22(10):1933-1937
49. Terpos E, Delimpasis S, Anargyrou K i wsp. The combination of bortezomib, doxorubicin and dexamethasone is an effective regimen for high risk, newly diagnosed patients with multiple myeloma, reduces bone resorption and normalizes angiopoetin 1 to angiopoetin 2 ratio. ASH annual meeting. Blood 2007; 110: 3596 (abstr.)
50. Warzocha K, Kraj M, Pogłód R, Kwaśniak B. Bortezomib in multiple myeloma: treatment and retreatment. A single center experience. Acta Pol Pharm. 2008; 65(6):753-756
51. Warzocha K, Kraj M, Pogłód R, i wsp. Efficacy and safety of thalidomide in the treatment of multiple myeloma. Acta Pol Pharm. 2008; 65(6): 771-774
52. Baur A., Stabler A., Nagel D. i wsp. Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon. Cancer. 2002 15; 95(6): 1334-1345